 |
| | Business Summary: NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. | | | Address
135 Wood St., Suite 205
West Haven
, CT 06516
Phone: 203-937-6137
Website: http://www.nanoviricides.com
| | Auditor |
|---|
Holtz Rubenstein Reminick
New York | | Transfer Agent |
|---|
Empire Stock Transfer Inc.
| Employees: 4
ShareHolders: 210 | Founded: 2000
Domicile: Nevada | | | |
| | NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus (HCV), Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company's products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide against rabies; and HCV, a Hepatitis C nanoviricide. It also provides HivCide-I, a drug project against HIV-I; HivCide-II, a targeted nanoviricide against HIV strains; and EKCCide-I, a nanoviricide drug, which indicates efficacy and safety of a drug candidate against the severe pink eye disease caused by adenoviruses called epidemic kerato-conjunctivitis. NanoViricides, Inc. has a pre-clinical study agreement with Thevac, LLC for the evaluation of the company's universal anti-influenza drug candidate FluCide; and has a research agreement with the University of California-San Francisco for testing of its anti-HIV drug candidates. The company was founded in 2005 and is headquartered in West Haven, Connecticut. | | History: INCORPORATED in Nevada Apr. 1, 2005 as Edot-com.com, Inc., and on Apr. 15, 2005, merged a Colorado company of the same name incorporated on July 25, 2000. Name changed to NanoViricides, Inc. June 28, 2005.
June 1, 2005, issued 80,000,000 Common shares to acquire NanoViricides, Inc., a privately owned Forida concern (incorporated on May 12, 2005). | | | | | | | | | |
|
Management
|
|---|
| Officers | Position |
|---|
| Anil Diwan | Chairman & President | | Eugene Seymour | Chief Executive Officer & Acting Chief Financial Officer |
| | Directors |
|---|
| Anil Diwan | | Eugene Seymour | | | |
| | | | Capitalization as of 06/30/2009: | | | | | Authorized Shares | Outstanding Shares |
|---|
| Common $0.001 par | 300,000,000 | 125,299,457 |
| | | | LONG TERM DEBT: None. | | | | Common $0.001 par | | | |
Stockholders:
06/30/2009,
210.
| | PRINCIPAL STOCKHOLDERS: June 30, 2009, TheraCour Pharma, Inc. owned or controlled 27.3% of the Common, Anil Diwan 8.8% and Eugene Seymour 6.8%. | | | |
Transfer Agent: Empire Stock Transfer Inc.
Henderson
, NV | | | | OTC Bulletin Board( Primary): NNVC | | | | Exchange | Year | High | Low |
|---|
| OTC Bulletin Board | 2009 | 1.2900 | 0.4100 | | OTC Bulletin Board | 2008 | 1.7800 | 0.3500 | | OTC Bulletin Board | 2007 | 1.4600 | 0.3300 | | Over The Counter | 2006 | 3.7500 | 0.6000 | | Over The Counter | 2005 | 1.2700 | 0.0320 |
|
| | | | DIVIDENDS: Common $0.001 par: No cash.
Common split 3.2-for-1, May 12, 2005. | | | | | |
| | Annual Report |
|---|
| | | Income Statement | |
| 2009 | 2008 |
|---|
| Research and development, net | 1,734 | 1,564 | | General and administrative | 1,086 | 1,228 | | Interest income | 32 | 54 | | Net income | (2,788) | (2,738) | | Share earns. basic | ($0.02) | ($0.02) | | Share earns. diluted | ($0.02) | ($0.02) |
| | | | Balance Sheet | |
| 2009 | 2008 |
|---|
| Assets: |
|
| | Cash & equiv. | 1,689 | 816 | | Other curr. assets | 109 | 103 | | Prepayments | 322 | 329 | | Tot. curr assets | 2,120 | 1,248 | | Net property | 689 | 134 | | Security deposit | -- | 80 | | Trademark | 192 | 7 | | Total assets | 3,001 | 1,468 | | Liabilities: |
|
| | Accts. pay. | 448 | 670 | | Accruals | 68 | 355 | | Tot. curr. liabs. | 516 | 1,025 | | Com. stk. p.$0.001 | 125 | 119 | | Paid-in cap. | 14,456 | 9,532 | | Stock subscription receivable | (100) | -- | | Retained earns. | (11,996) | (9,208) | | Total liabs. | 3,001 | 1,468 |
| | | |
* Effective June 1, 2005, Edot-com.com, Inc. (ECMM) issued 80,000,000 com. shs. for all of the outstanding shs. of Nanoviricide, Inc. (NVI). Transaction was acctd. for as a reverse acquis., with NVI being deemed the acquiring company. On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. | | | |
| | Interim Report
|
|---|
| | | Data Not Available | | | | | | | | | |
| | Pro Forma Report
|
|---|
| | | Data Not Available | | | | | | | | | |
| | Quarterly Report Information
|
|---|
| | | Quarterly Revenue, US$ |
|---|
| Year | Quarter | Revenue | | 2009 |
1 | Nil | | 2009 |
2 | Nil | | 2009 |
3 | Nil | | 2009 |
Full Year
| Nil | | 2008 |
1 | Nil | | 2008 |
2 | Nil | | 2008 |
3 | Nil | | 2008 |
4 | Nil | | 2008 |
Full Year
| Nil | | 2007 |
2 | Nil | | 2007 |
3 | Nil | | 2007 |
Full Year
| Nil | | 2006 |
Full Year
| Nil |
| | | | | | Quarterly Net Income, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | (730,000) | | 2010 |
2 | (930,000) | | 2010 |
3 | (2,420,000) | | 2009 |
1 | (740,000) | | 2009 |
2 | (630,000) | | 2009 |
3 | (790,000) | | 2009 |
4 | (620,000) | | 2009 |
Full Year
| (2,790,000) | | 2008 |
1 | (570,000) | | 2008 |
2 | (380,000) | | 2008 |
3 | (790,000) | | 2008 |
4 | (990,000) | | 2008 |
Full Year
| (2,740,000) | | 2007 |
2 | (690,000) | | 2007 |
3 | (920,000) | | 2007 |
Full Year
| (3,120,000) | | 2006 |
Full Year
| (3,230,000) | | 2005 |
Full Year
| (430,000) |
| | | | | | Quarterly EPS, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | (.01) | | 2010 |
2 | (.01) | | 2010 |
3 | (.02) | | 2009 |
1 | (.01) | | 2009 |
2 | Nil | | 2009 |
3 | (.01) | | 2009 |
4 | (.01) | | 2009 |
Full Year
| (.02) | | 2008 |
1 | (.01) | | 2008 |
2 | Nil | | 2008 |
3 | (.01) | | 2008 |
4 | (.01) | | 2008 |
Full Year
| (.02) | | 2007 |
1 | (.01) | | 2007 |
2 | (.01) | | 2007 |
3 | (.01) | | 2007 |
4 | (.01) | | 2007 |
Full Year
| (.03) | | 2006 |
1 | Nil | | 2006 |
2 | (.01) | | 2006 |
3 | (.01) | | 2006 |
4 | (.01) | | 2006 |
Full Year
| (.03) |
| | | |
| |
|
